refractory glioblastoma (phase II)

Overview of attention for article published in Journal of Neuro-Oncology, August 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 260 followers.

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). https://t.co/DizdntHSz4

10 Aug 2019

Reply Repost Favourite